First Clinical Experience of ⁶⁸Ga-FAPI PET/CT in Tertiary Cancer Center: Identifying Pearls and Pitfalls.

ABSTRACT: Background/Objectives: Over the past four years, ⁶⁸Ga-fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) has been established at a tertiary cancer care facility in Jordan. This retrospective study aims to explore tracer uptake metrics across various epithelial neoplasms, identify diagnostic pitfalls associated with ⁶⁸Ga-FAPI PET/CT, and evaluate the influence of ⁶⁸Ga-FAPI PET/CT staging results on changes in therapeutic intent compared to gold standard molecular imaging modalities. Methods: A total of 48 patients with biopsy-confirmed solid tumors underwent 77 ⁶⁸Ga-FAPI PET/CT examinations for molecular imaging assessment, encompassing neoplasms originating from the gastrointesti

SUBMITTER: Al-Ibraheem A 

PROVIDER: S-EPMC11764383 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature